BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Phase 1

Recruiting

Conditions: Relapsed or Refractory T-cell Lymphomas

Interventions: Drug: BMS-986369

First Posted Date: 2023-09-13

Last Posted Date: 2025-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 85

Registration Number: NCT06035497

Locations: 🇯🇵
Anjo Kosei Hospital, Anjo-shi, Aichi, Japan
🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵
Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan

and more 37 locations

A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants

Phase 1

Withdrawn

Conditions: Healthy Adult Volunteers

Interventions: Drug: BMS-986196

First Posted Date: 2023-09-13

Last Posted Date: 2023-09-21

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT06034899

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Danicamtiv

First Posted Date: 2023-09-07

Last Posted Date: 2023-11-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 21

Registration Number: NCT06027437

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986466
Drug: Adagrasib
Drug: Cetuximab

First Posted Date: 2023-09-06

Last Posted Date: 2024-06-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT06024174

Locations: 🇺🇸
Local Institution - 0025, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 0047, Los Angeles, California, United States
🇦🇺
Local Institution - 0053, Westmead, New South Wales, Australia

and more 6 locations

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Phase 3

Recruiting

Conditions: Progressive Pulmonary Fibrosis

Interventions: Drug: BMS-986278
Drug: BMS-986278 Placebo

First Posted Date: 2023-09-06

Last Posted Date: 2025-05-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1092

Registration Number: NCT06025578

Locations: 🇮🇳
Local Institution - 0407, Ahmedabad, Gujarat, India
🇮🇳
Marengo CIMS Hospital, Ahmedabad, Gujarat, India
🇮🇳
Local Institution - 0491, Vadodara, Gujarat, India

and more 529 locations

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

Phase 1

Recruiting

Conditions: Lupus

Interventions: Drug: BMS-986326
Other: Placebo for BMS-986326

First Posted Date: 2023-08-28

Last Posted Date: 2024-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT06013995

Locations: 🇺🇸
North Georgia Rheumatology, Lawrenceville, Georgia, United States
🇲🇽
Local Institution - 0077, Chihuahua, Mexico
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

and more 18 locations

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Phase 3

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BMS-986278
Drug: BMS-986278 Placebo

First Posted Date: 2023-08-22

Last Posted Date: 2025-05-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1185

Registration Number: NCT06003426

Locations: 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Local Institution - 0179, Jasper, Alabama, United States
🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

and more 500 locations

A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Drospirenone/Ethinyl Estradiol
Drug: BMS-986278

First Posted Date: 2023-08-14

Last Posted Date: 2024-01-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 37

Registration Number: NCT05985590

Locations: 🇨🇦
Local Institution - 0002, Québec, Quebec, Canada

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: [14C]-BMS-986196

First Posted Date: 2023-08-08

Last Posted Date: 2023-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT05981963

Locations: 🇺🇸
Labcorp Clinical Research Unit - Madison, Madison, Wisconsin, United States

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Biological: Abatacept

First Posted Date: 2023-08-08

Last Posted Date: 2024-07-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 174

Registration Number: NCT05981976

Locations: 🇺🇸
Local Institution, Las Vegas, Nevada, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy